PL4554562T3 - Kompozycje olanzapiny i sposoby zastosowania - Google Patents
Kompozycje olanzapiny i sposoby zastosowaniaInfo
- Publication number
- PL4554562T3 PL4554562T3 PL24700866.7T PL24700866T PL4554562T3 PL 4554562 T3 PL4554562 T3 PL 4554562T3 PL 24700866 T PL24700866 T PL 24700866T PL 4554562 T3 PL4554562 T3 PL 4554562T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- olanzapine compositions
- olanzapine
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363479267P | 2023-01-10 | 2023-01-10 | |
| US202363516283P | 2023-07-28 | 2023-07-28 | |
| PCT/EP2024/050429 WO2024149778A1 (en) | 2023-01-10 | 2024-01-10 | Olanzapine compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4554562T3 true PL4554562T3 (pl) | 2026-02-09 |
Family
ID=89661117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL24700866.7T PL4554562T3 (pl) | 2023-01-10 | 2024-01-10 | Kompozycje olanzapiny i sposoby zastosowania |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20240238308A1 (pl) |
| EP (2) | EP4691491A3 (pl) |
| JP (1) | JP2026501805A (pl) |
| KR (1) | KR20250129781A (pl) |
| CN (1) | CN120569188A (pl) |
| AU (1) | AU2024208071A1 (pl) |
| CA (1) | CA3266264A1 (pl) |
| CL (1) | CL2025002025A1 (pl) |
| DK (1) | DK4554562T3 (pl) |
| ES (1) | ES3055278T3 (pl) |
| FI (1) | FI4554562T3 (pl) |
| HR (1) | HRP20251423T1 (pl) |
| IL (1) | IL321134A (pl) |
| LT (1) | LT4554562T (pl) |
| MX (1) | MX2025008012A (pl) |
| PE (1) | PE20252752A1 (pl) |
| PL (1) | PL4554562T3 (pl) |
| PT (1) | PT4554562T (pl) |
| RS (1) | RS67477B1 (pl) |
| SI (1) | SI4554562T1 (pl) |
| SM (1) | SMT202500442T1 (pl) |
| WO (1) | WO2024149778A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026003357A1 (en) | 2024-06-28 | 2026-01-02 | Teva Pharmaceuticals International Gmbh | Medicament delivery kit |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| EG23659A (en) | 1995-03-24 | 2007-03-26 | Lilly Co Eli | Process and crystal forms of methyl-thieno-benzodiazepine |
| FR2741628B1 (fr) | 1995-11-29 | 1998-02-06 | Centre Nat Rech Scient | Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs |
| AU2003300324A1 (en) | 2002-12-24 | 2004-07-22 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms |
| CN101106972A (zh) * | 2004-11-16 | 2008-01-16 | 伊兰制药国际有限公司 | 注射用纳米微粒奥氮平制剂 |
| US9023897B2 (en) | 2010-12-29 | 2015-05-05 | Medincell | Biodegradable drug delivery compositions |
| EP3352735B1 (en) * | 2015-09-21 | 2023-08-30 | Teva Pharmaceuticals International GmbH | Sustained release olanzapine formulations |
| EP3655017B1 (en) * | 2017-07-17 | 2025-01-22 | Medincell S.A. | Pharmaceutical composition |
| MX2022003051A (es) * | 2019-09-13 | 2022-06-14 | Medincell S A | Formulaciones para la administracion de farmacos. |
| JP2024511353A (ja) * | 2021-03-17 | 2024-03-13 | メドインセルル エス．エー． | リスペリドン及び生分解性ポリマーを含む長時間作用型注射用製剤 |
-
2024
- 2024-01-10 JP JP2025540292A patent/JP2026501805A/ja active Pending
- 2024-01-10 LT LTEPPCT/EP2024/050429T patent/LT4554562T/lt unknown
- 2024-01-10 FI FIEP24700866.7T patent/FI4554562T3/fi active
- 2024-01-10 SM SM20250442T patent/SMT202500442T1/it unknown
- 2024-01-10 RS RS20251206A patent/RS67477B1/sr unknown
- 2024-01-10 CN CN202480007112.1A patent/CN120569188A/zh active Pending
- 2024-01-10 EP EP25200894.1A patent/EP4691491A3/en active Pending
- 2024-01-10 WO PCT/EP2024/050429 patent/WO2024149778A1/en not_active Ceased
- 2024-01-10 DK DK24700866.7T patent/DK4554562T3/da active
- 2024-01-10 PT PT247008667T patent/PT4554562T/pt unknown
- 2024-01-10 PL PL24700866.7T patent/PL4554562T3/pl unknown
- 2024-01-10 AU AU2024208071A patent/AU2024208071A1/en active Pending
- 2024-01-10 KR KR1020257025957A patent/KR20250129781A/ko active Pending
- 2024-01-10 EP EP24700866.7A patent/EP4554562B1/en active Active
- 2024-01-10 ES ES24700866T patent/ES3055278T3/es active Active
- 2024-01-10 HR HRP20251423TT patent/HRP20251423T1/hr unknown
- 2024-01-10 US US18/409,158 patent/US20240238308A1/en active Pending
- 2024-01-10 PE PE2025001406A patent/PE20252752A1/es unknown
- 2024-01-10 SI SI202430011T patent/SI4554562T1/sl unknown
- 2024-01-10 CA CA3266264A patent/CA3266264A1/en active Pending
- 2024-06-07 US US18/736,965 patent/US12220418B2/en active Active
-
2025
- 2025-05-26 IL IL321134A patent/IL321134A/en unknown
- 2025-07-08 MX MX2025008012A patent/MX2025008012A/es unknown
- 2025-07-09 CL CL2025002025A patent/CL2025002025A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4554562A1 (en) | 2025-05-21 |
| LT4554562T (lt) | 2025-12-10 |
| HRP20251423T1 (hr) | 2025-12-19 |
| WO2024149778A1 (en) | 2024-07-18 |
| CA3266264A1 (en) | 2024-07-18 |
| FI4554562T3 (fi) | 2025-11-25 |
| EP4691491A3 (en) | 2026-03-04 |
| US20240238308A1 (en) | 2024-07-18 |
| DK4554562T3 (da) | 2025-12-01 |
| EP4554562B1 (en) | 2025-09-10 |
| KR20250129781A (ko) | 2025-08-29 |
| CN120569188A (zh) | 2025-08-29 |
| PE20252752A1 (es) | 2025-12-05 |
| JP2026501805A (ja) | 2026-01-16 |
| ES3055278T3 (en) | 2026-02-10 |
| SMT202500442T1 (it) | 2026-01-12 |
| MX2025008012A (es) | 2025-08-01 |
| CL2025002025A1 (es) | 2025-11-07 |
| EP4691491A2 (en) | 2026-02-11 |
| AU2024208071A1 (en) | 2025-06-12 |
| RS67477B1 (sr) | 2025-12-31 |
| US12220418B2 (en) | 2025-02-11 |
| PT4554562T (pt) | 2025-11-25 |
| US20240325408A1 (en) | 2024-10-03 |
| IL321134A (en) | 2025-07-01 |
| SI4554562T1 (sl) | 2026-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL309073A (en) | Enantiomeric entactogen compounds and methods of their use. | |
| PT4267105T (pt) | Composições de anticorpos e métodos de utilização das mesmas | |
| IL308041A (en) | Collagen compositions and methods of using them | |
| IL316619A (en) | PI3Kα inhibitors and methods of using them | |
| IL314320A (en) | Compounds and methods of use | |
| GB2622995B (en) | CAS13-based compositions and methods of use thereof | |
| IL312928A (en) | Complement Factor B Modulating Preparations and Methods for Using Them | |
| PL4090332T3 (pl) | Kompozycje podstawionych pirazolopirymidyn i ich zastosowania | |
| IL316049A (en) | Musuntuzumab pharmaceutical preparations and methods of use | |
| IL318393A (en) | Azaquinazoline compounds and methods of use | |
| IL321134A (en) | Olanzapine compounds and methods of use | |
| IL315862A (en) | Angiotensinogen modulators and methods of using them | |
| IL325628A (en) | Coagulation factor xi modulators and methods of using them | |
| IL314277A (en) | Anti-B7-H3 compounds and methods of use | |
| IL314226A (en) | Designed cytokine compositions and methods of use | |
| IL314293A (en) | Olanzapine, its compounds and methods of using it | |
| IL312205A (en) | Coxsackievirus B compounds and methods of using them | |
| IL326294A (en) | Epilepsy compositions and methods of use | |
| GB202313643D0 (en) | Serping1-sarna compositions and methods of use | |
| GB202310868D0 (en) | compositions and methods of use | |
| IL325884A (en) | Compositions comprising GAL475 and methods of using them | |
| GB202119051D0 (en) | Wingsail and method of use | |
| IL311518A (en) | Preparations that modulate perkalkerine and methods of using them | |
| GB202405768D0 (en) | Compositions and uses of oligo-chromopeptides and methods of making | |
| GB202315697D0 (en) | Compounds and methods of use |